Research programme: inflammatory bowel disease CAR-T cell therapies - Sonoma Biotherapeutics
Alternative Names: SBT-77-7200 seriesLatest Information Update: 28 Sep 2025
At a glance
- Originator Sonoma Biotherapeutics
- Class CAR-T cell therapies; Gene therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Inflammatory bowel diseases
Most Recent Events
- 28 Sep 2025 No recent reports of development identified for research development in Inflammatory-bowel-diseases in USA (Parenteral)
- 18 Aug 2021 SBT 77 7200 is available for licensing as of 18 Aug 2021. https://www.sonomabio.com/#contact
- 04 Aug 2021 Early research in Inflammatory bowel diseases in USA (Parenteral)